Latest Insider Transactions at Amylyx Pharmaceuticals, Inc. (AMLX)
This section provides a real-time view of insider transactions for Amylyx Pharmaceuticals, Inc. (AMLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Amylyx Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Amylyx Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2025
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+18.48%
|
-
|
|
Mar 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+24.86%
|
-
|
|
Mar 06
2025
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,851
+24.46%
|
-
|
|
Mar 03
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.15 P/Share
|
|
Mar 03
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,611
-1.19%
|
$4,833
$3.12 P/Share
|
|
Mar 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.17 P/Share
|
|
Feb 24
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,169
-3.0%
|
$12,507
$3.15 P/Share
|
|
Feb 05
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,310
+1.12%
|
$36,310
$1.57 P/Share
|
|
Feb 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,851
-0.37%
|
$35,553
$3.47 P/Share
|
|
Feb 03
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,678
-2.58%
|
$11,034
$3.49 P/Share
|
|
Feb 03
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,855
-0.37%
|
$35,565
$3.47 P/Share
|
|
Jan 24
2025
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
27,910
-3.25%
|
-
|
|
Jan 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,471
-0.23%
|
$29,884
$4.04 P/Share
|
|
Jan 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,471
-0.23%
|
$29,884
$4.05 P/Share
|
|
Dec 02
2024
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,421
-3.77%
|
$27,105
$5.54 P/Share
|
|
Nov 04
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,690
+1.96%
|
$63,690
$1.57 P/Share
|
|
Sep 30
2024
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,442
-7.37%
|
$34,326
$3.2 P/Share
|
|
Sep 30
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,589
-0.57%
|
$55,767
$3.2 P/Share
|
|
Sep 30
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,589
-0.59%
|
$55,767
$3.2 P/Share
|
|
Sep 30
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,709
-5.75%
|
$26,127
$3.2 P/Share
|
|
Sep 23
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,857
+0.06%
|
$1,857
$1.57 P/Share
|
|
Sep 12
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,449
+1.05%
|
$34,449
$1.57 P/Share
|
|
Sep 12
2024
|
James M Frates Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+14.63%
|
$80,000
$2.53 P/Share
|
|
Sep 05
2024
|
Karen Firestone |
BUY
Open market or private purchase
|
Direct |
50,000
+47.62%
|
$100,000
$2.13 P/Share
|
|
Sep 03
2024
|
George M Milne Jr |
BUY
Open market or private purchase
|
Direct |
100,000
+10.43%
|
$200,000
$2.2 P/Share
|
|
May 15
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,455
-6.46%
|
$10,455
$1.88 P/Share
|
|
May 15
2024
|
Daphne Quimi |
BUY
Open market or private purchase
|
Direct |
2,250
+31.03%
|
$2,250
$1.89 P/Share
|
|
May 14
2024
|
Daphne Quimi |
BUY
Open market or private purchase
|
Direct |
2,750
+50.0%
|
$2,750
$1.88 P/Share
|
|
Apr 16
2024
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,910
+38.43%
|
-
|
|
Apr 16
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
179,850
+5.42%
|
-
|
|
Apr 16
2024
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,560
+33.22%
|
-
|
|
Apr 16
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
179,850
+5.32%
|
-
|
|
Apr 16
2024
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,180
+28.75%
|
-
|
|
Mar 05
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,540
-1.86%
|
$27,720
$18.73 P/Share
|
|
Mar 05
2024
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,792
-1.31%
|
$32,256
$18.73 P/Share
|
|
Mar 05
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,135
-0.14%
|
$74,430
$18.73 P/Share
|
|
Mar 05
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,135
-0.14%
|
$74,430
$18.73 P/Share
|
|
Feb 26
2024
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+20.83%
|
-
|
|
Feb 26
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+4.1%
|
-
|
|
Feb 26
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+4.02%
|
-
|
|
Feb 26
2024
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,667
+30.66%
|
-
|
|
Feb 23
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,838
-5.78%
|
$51,084
$18.76 P/Share
|
|
Jan 25
2024
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
9,100
-1.19%
|
-
|
|
Jan 16
2024
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
94,350
-10.95%
|
-
|
|
Jan 09
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,841
-0.2%
|
$93,456
$16.33 P/Share
|
|
Jan 09
2024
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,716
-2.37%
|
$43,456
$16.33 P/Share
|
|
Jan 09
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,841
-0.21%
|
$93,456
$16.33 P/Share
|
|
Jan 09
2024
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,812
-1.35%
|
$44,992
$16.33 P/Share
|